Skip to content

Clinical study on the treatment of early diabetic nephropathy with Liuwei Tangshen Decoction

Clinical study on the treatment of early diabetic nephropathy with Liuwei Tangshen Decoction

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088292
Enrollment
Unknown
Registered
2024-08-15
Start date
2023-12-15
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early diabetic nephropathy

Interventions

Single case group:Liuwei Tangshen Decoction optimization formula
Single case group:Liuwei Tangshen Decoction optimization formula placebo

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: diabetic kidney disease,DKD 1. A clear history of type 2 diabetes; 2. Meet the early diagnosis criteria of type 2 diabetic nephropathy; 3. Age 18-70 years old; 4. Consistent with Qi deficiency and blood stasis, water-heat interjunction syndrome; 5. No ketoacidosis, hyperosmolar coma, repeated severe hypoglycemia in the past 3 months; 6. Sign informed consent; 7. Can provide detailed contact information, no short-term migration, willing to cooperate with follow-up.

Exclusion criteria

Exclusion criteria: 1. Increased urinary microalbumin excretion rate caused by other primary diseases (chronic nephritis, hypertension, gout, lupus erythematosus, etc.); 2. Renal vascular hypertension; 3. Patients with malignant hypertension, myocardial infarction, cerebrovascular accident and other critical medical history within six months; 4. Patients with congestive heart failure grade I-IV; 5. There are serious infections in the near future (within 4 weeks); 6. Patients with serious primary diseases such as heart, liver, brain, kidney and hematopoietic system, cancer and mental illness; 7. Pregnant or planning pregnancy, breastfeeding women; 8. People who are known to be allergic to such drugs or have severe allergies; 9. Patients who have participated in other clinical drug trials within the last 3 months; 10. Researchers consider it inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
UACR;eGFR;TCM symptom score scale;glycosylated hemoglobin;blood sugar;urinalysis;Urinary creatinine;liver function;renal function;

Countries

China

Contacts

Public ContactFan Ting

Beijing Hospital

nancy_0116@163.com+86 138 1151 6228

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026